ONConcept®: An Integrated European Hub for Delivering Highly Potent Complex Products

We're thrilled to share our latest news!

Our innovative nanoenzalutamide tablet development is strengthened by the recent decision of the European Patent Office to maintain Medivation/Astellas formulation patent EP3725778 B1 covering Xtandi® tablet formulation, which represents a relevant barrier for Generics.

What sets our innovation apart? Our proprietary nanoenzalutamide tablet formulation has been developed as an alternative to the amorphous solid dispersion to enable a more patient-centric alternative to Xtandi® tablets and paves the way for a timely market entry as early as 2028.

This shows the commitment to innovation of the ONConcept® consortium (Bluepharma, HELM AG and WELDING GmbH & Co. KG) in partnership with Nanoform and our relentless pursuit of advancing healthcare solutions.

Stay tuned!

Media

Our innovative nanoenzalutamide tablet development is strengthened by the recent decision of the European Patent Office

ONConcept — April 2024

Our innovative nanoenzalutamide tablet development is strengthened by the recent decision of the European Patent Office to maintain Medivation/Astellas formulation patent EP3725778 B1...

ONConcept® has successfully completed the pivotal BE study for Nilotinib

ONConcept — January 2024

ONConcept® announces the successful completion of a positive bioequivalence (BE) study in the European Union for Nilotinib.The study marks a significant milestone in our commitment to...

ONConcept® has successfully completed the pivotal BE study for Pomalidomide

ONConcept — June 2023

Bluepharma, a Portuguese pharmaceutical company, has just opened a state-of-the-art industrial unit specialized in the production of oral solid high potent drugs, namely in the oncology area.

Bluepharma opens an industrial unit unique in Portugal and one of the largest in Europe

ONConcept — March 2023

Bluepharma, a Portuguese pharmaceutical company, has just opened a state-of-the-art industrial unit specialized in the production of oral solid high potent drugs, namely in the oncology area.

How an Integrated European Hub for Complex Products is unlocking major market opportunities

Pharma Intelligence — October 2022

The need for an integrated European developer and manufacturer of complex, differentiated and highly potent products is clearer than ever. Expirations on the patents and/or regulatory...

ONConcept®: An Integrated European Hub for Delivering Highly Potent Complex Products

Pharma Intelligence — July 2021

Off-patent, highly potent pharmaceuticals represent a major opportunity. The companies that seize the opportunity will grow sales by delivering products that improve the lives of patients...